TGFB1 and Alzheimer disease: We next compared the effect on hBMSC differentiation to AD when TGFβ1 (10 ng/ml) treatment was conducted as a single pulse dose during the commitment phase of differentiation (day −2 to day 0) versus continuous treatment during the whole course of differentiation (day −2 to day 7) (Fig. 2A).